Peter Mu
Directeur Général chez Teamedon International, Inc.
Profil
Peter Mu is currently the President & Chief Executive Officer at Teamedon International, Inc. Prior to this, he worked as a Study Director at Labcorp Drug Development, Inc. from 2005 to 2008 and as an Associate Director at Lexicon Pharmaceuticals, Inc. from 2008 to 2009.
Dr. Mu holds a doctorate degree from North Carolina State University and an MBA from Carey Business School.
Postes actifs de Peter Mu
| Sociétés | Poste | Début |
|---|---|---|
Teamedon International, Inc.
 Teamedon International, Inc. Pharmaceuticals: MajorHealth Technology Teamedon International, Inc. develops novel therapeutics to combat leukemia. The company was founded on May 22, 2017 and is headquartered in Lewes, DE. | Directeur Général | - |
Anciens postes connus de Peter Mu
| Sociétés | Poste | Fin |
|---|---|---|
| LEXICON PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/01/2009 |
| COVANCE INC. | Corporate Officer/Principal | 01/04/2008 |
Formation de Peter Mu
| North Carolina State University | Doctorate Degree |
| Carey Business School | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| LEXICON PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Labcorp Drug Development, Inc.
 Labcorp Drug Development, Inc. Pharmaceuticals: MajorHealth Technology Covance, Inc. operates as a contract research organization and drug development company. Its services include research, lead optimization, analysis services, safety assessment and drug safety testing, consulting and partnering, clinical development, informatics, clinical testing, commercialization, and manufacturing support. The company was founded on November 12, 1996 and is headquartered in Princeton, NJ. | Health Technology |
Teamedon International, Inc.
Teamedon International, Inc. Pharmaceuticals: MajorHealth Technology Teamedon International, Inc. develops novel therapeutics to combat leukemia. The company was founded on May 22, 2017 and is headquartered in Lewes, DE. | Health Technology |